Drug
Aln 4324
Aln 4324: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-4324 NCT07465224 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) |
| ALN-4324 NCT06845202 | Phase 1/2 | Obese or Overweight Healthy Volunteers |
Latest
No recent events.
Follow Aln 4324 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.